Pediatric Hematology/Oncology

Hodgkin Lymphoma

Questions discussed in this category

Is your standard of care for newly diagnosed advanced classical Hodgkin now nivolumab-AVD based on SWOG 1826?

For patients with Stage IIIB or IV HD flowing Bv-AVEPC with initial large mediastinal adenopathy, how can we avoid ISRT?

Per the NCCN guideline for HR HD, if treated per OEPA-COPDAC, you can omit ISRT. This patient received treatment per AHOD1331, which recommends ISRT f...

2 Answers available

Is it appropriate to substitute vincristine for vinblastine in ABVD for systemic therapy of Hodgkins lymphoma?

Given nationwide shortage in vinblastine, several of my patients under active therapy are facing delays in their therapies. Is it appropriate to subst...

1 Answer available

What cardiac surveillance would you do for an asymptomatic male patient with a remote history of mantle field radiation for Hodgkin's lymphoma?

1 Answer available

How do you approach delivering ISRT to nodular lymphocyte predominant Hodgkin Lymphoma that has responded on FDG-PET/CT after chemotherapy?

Does the stage at diagnosis affect your decision?

1 Answer available

Does the use of A+AVD versus ABVD affect your decision for consolidation RT for bulky Hodgkin lymphoma?

1 Answer available

Is there any scenario where you would consider treating a relapsed AYA patient with Hodgkin Lymphoma without consolidative auto transplant?

If so, what treatment regimen would you recommend?

1 Answer available

Can Hodgkin-like PTLD be treated with Rituximab and weaning of immunosuppression, or is Hodgkin-directed chemotherapy necessary for cure?

1 Answer available

What is your first line of therapy for refractory Hodgkin lymphoma in an AYA patient?

1 Answer available

How do you define bulky disease for Hodgkin's lymphoma which is outside the mediastinum?

Do you use a cutoff of 10 cm? Do you measure the size of the largest node or measure the largest conglomerate or measure the total length of the entir...

1 Answer available

How do you interpret a Deauville score of 3 on PET when performing mid-treatment assessments in patients with Hodgkin lymphoma?

Are there situations in which a Deauville 3 would cause you to escalate therapy?

2 Answers available

How would you treat a young patient with classical intermediate-risk Hodgkin lymphoma who has an underlying DNA repair-deficiency disorder, such as congenital mismatch repair disorder or ataxia telangiectasia?

How does your treatment approach vary depending on the underlying predisposition?

1 Answer available

How long should patients treated with frontline therapy for Hodgkin lymphoma wait before attempting to conceive a child?

Do your recommendations differ between those who receive ABVD and escalated BEACOPP? Do you recommend consultation with fertility specialists for all...

1 Answer available

Do you think there is any compelling data to support giving brentuximab as frontline therapy for pediatric patients with Hodgkin lymphoma?

Results of AHOD1331 are not yet known, but adults have started using Brentuximab upfront for high risk patients

1 Answer available

What is the preferred treatment approach for an AYA patient with intermediate to high risk Hodgkin lymphoma: The pediatric approach (ABVE-PC +/- radiation) or the adult approach (ABVD with possible escalation to BEACOPP)?

1 Answer available

When do you consider including Rituximab into the treatment regimen for a pediatric or AYA patient with intermediate and advanced-stage nodular lymphocyte-predominant Hodgkin lymphoma?

1 Answer available

Is dexrazoxane recommended for cardioprotection in AYA patients with Hodgkin lymphoma who are receiving anthracyclines as part of their upfront therapy?

3 Answers available

For AYA patients with early-stage Hodgkin's lymphoma being treated with ABVD, how many cycles of chemotherapy do you administer, and when can radiation be avoided?

Have the RAPID or CALGB 5064 studies changed your treatment approach?

2 Answers available

In what situations do you utilize G-CSF in germ cell tumors or Hodgkin lymphoma patients receiving bleomycin?

There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.

2 Answers available

What treatment would you recommend to effectively treat a pediatric patient newly diagnosed with low risk Hodgkin's lymphoma while minimizing the risk of late toxicity?

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-10

Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031.

Chest, 1997-03

Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.

J. Clin. Oncol.,

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

Clin Genitourin Cancer, 2017 Sep 04

Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.

Eur. Urol., 2020 Jan 01

The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.

N. Engl. J. Med., 2015-04-23

Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

J. Clin. Oncol., 2019 Sep 10

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.

Blood, 2018 Sep 6

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

J Clin Oncol, 2017 Mar 14

Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20

Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.

J Clin Oncol, 2020 Apr 28

Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Blood, 2009-09-03

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

N. Engl. J. Med., 2018-01-25

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

J Clin Oncol, 2021 Apr 07

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.

Clin Transl Oncol, 2020 Sep 17

ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.

J Assist Reprod Genet, 2020 Jun 02

Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.

Lancet Oncol, 2018 Sep 13

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.

British journal of haematology, 2014-06

F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.

International journal of radiation oncology, biology, physics, 2019-06-01

Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.

Blood, 2018-07-05

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Blood,

Getting to transplant in Hodgkin lymphoma: BVB.

Blood,

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.

J Clin Oncol, 2021 Jun 25

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-09-20

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Blood, 2016-11-24

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

Lancet, 2012 Apr 04

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Blood, 2018 Aug 30

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.

Ann Oncol,

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.

Journal of the National Comprehensive Cancer Network : JNCCN, 2012-05

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-09-15

Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.

Cancer, 2010-09-15

Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients.

Pediatric blood & cancer, 2006-03

APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial.

Pediatric blood & cancer, 2014-04

Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-20

Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-05-01

Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.

Annals of oncology : official journal of the European Society for Medical Oncology, 2011-02

Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.

Pediatric blood & cancer, 2015-01

Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.

The Lancet. Oncology, 2018-09

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.

N Engl J Med, 2022 Nov 03

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.

Lancet, 1993 Apr 24

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Lancet, 2002 Jun 15

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Crit Rev Oncol Hematol, 2014 May 02

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis.

Br J Haematol, 2014 Feb 07

Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.

Blood, 2023 Apr 27

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.

J Clin Oncol, 2005 Sep 01

Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.

J Pediatr Hematol Oncol, 2004 Nov

Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease.

Hemasphere, 2020 Jan 10

Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group.

J Pediatr Hematol Oncol, 2001 Jan

Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.

Br J Cancer, 1992 Dec

Outcome of children with resistant and relapsed Hodgkin's disease.

Int J Radiat Oncol Biol Phys, 2001 Dec 01

Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial.

J Clin Oncol, 2007 Apr 09

Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.

Pediatric blood & cancer, 2019-08

Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.

J Clin Oncol, 2022 Jul 22

Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

The New England journal of medicine, 2022 Jul 13

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

The New England journal of medicine, 2024 Oct 17

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

Pediatric Hematology/Oncology

Hodgkin Lymphoma

Questions discussed in this category

Papers discussed in this category

Related Topics in Pediatric Hematology/Oncology